For the more than 100 million Americans dealing with skin conditions, there’s an alternative to cumbersome, archaic ...
Cullinan is prioritizing safety and meaningful monotherapy efficacy for autoimmune indications, targeting Grade 2 cytokine release syndrome rates of around 10% or less and aiming for "treatment‑free ...
Cullinan Therapeutics, Inc. has announced the European Medicines Agency's approval of its Clinical Trial Application for CLN-978, a CD19-targeting bispecific T cell engager, aiming to initiate a Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results